SG Americas Securities LLC Raises Stake in United Therapeutics Corporation $UTHR

SG Americas Securities LLC boosted its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 109.8% during the third quarter, Holdings Channel.com reports. The firm owned 14,297 shares of the biotechnology company’s stock after acquiring an additional 7,483 shares during the quarter. SG Americas Securities LLC’s holdings in United Therapeutics were worth $5,993,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in UTHR. Chung Wu Investment Group LLC bought a new stake in shares of United Therapeutics in the 2nd quarter worth approximately $29,000. WealthCollab LLC raised its stake in United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 38 shares during the last quarter. Rakuten Securities Inc. boosted its holdings in United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 46 shares in the last quarter. Geneos Wealth Management Inc. grew its stake in shares of United Therapeutics by 141.7% in the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 85 shares during the last quarter. Finally, True Wealth Design LLC increased its holdings in shares of United Therapeutics by 738.5% during the third quarter. True Wealth Design LLC now owns 109 shares of the biotechnology company’s stock valued at $46,000 after acquiring an additional 96 shares in the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

United Therapeutics Stock Performance

United Therapeutics stock opened at $483.23 on Friday. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $519.99. The firm has a 50 day moving average price of $483.94 and a 200 day moving average price of $402.27. The company has a market capitalization of $20.81 billion, a PE ratio of 18.31, a price-to-earnings-growth ratio of 2.51 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, beating analysts’ consensus estimates of $6.89 by $0.27. The company had revenue of $799.50 million for the quarter, compared to analysts’ expectations of $812.87 million. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.United Therapeutics’s quarterly revenue was up 6.8% on a year-over-year basis. During the same period last year, the firm earned $6.39 earnings per share. As a group, equities research analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Insider Activity

In other news, EVP Paul A. Mahon sold 8,300 shares of the stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $485.43, for a total value of $4,029,069.00. Following the completion of the sale, the executive vice president owned 36,781 shares of the company’s stock, valued at $17,854,600.83. This represents a 18.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Louis W. Sullivan sold 5,950 shares of the company’s stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $512.13, for a total value of $3,047,173.50. The SEC filing for this sale provides additional information. Insiders have sold a total of 608,514 shares of company stock worth $284,376,421 in the last quarter. Corporate insiders own 10.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on UTHR. HC Wainwright upped their price target on shares of United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Jefferies Financial Group reiterated a “buy” rating and issued a $575.00 target price on shares of United Therapeutics in a research note on Wednesday, November 19th. Wells Fargo & Company lifted their price target on shares of United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 30th. Morgan Stanley set a $447.00 price objective on United Therapeutics in a research note on Wednesday, October 29th. Finally, Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. Eight research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $509.50.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.